Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

The availability of tyrosine kinase inhibitors (TKI) during the past ten years has led to improved response and overall survival of patients suffering from metastatic clear cell renal cell carcinoma (ccRCC). However, most of these tumors will eventually progress due to resistance evolving under ther...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2017-09, Vol.8 (43), p.74049-74057
Hauptverfasser:	Dietz, Steffen, Sültmann, Holger, Du, YueJun, Reisinger, Eva, Riediger, Anja Lisa, Volckmar, Anna-Lena, Stenzinger, Albrecht, Schlesner, Matthias, Jäger, Dirk, Hohenfellner, Markus, Duensing, Stefan, Grüllich, Carsten, Pahernik, Sascha
Format:	Artikel
Sprache:	eng
Schlagworte:	Research Paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!